A Phase 1/2 Study of the Combination of RDEA119 and Sorafenib in Patients With Advanced Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 20 Oct 2016
At a glance
- Drugs Refametinib (Primary) ; Sorafenib (Primary)
- Indications Breast cancer; Colorectal cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors Bayer
- 07 Dec 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.